Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial
A series of dose-ranging and tolerability studies of intravenous levosimendan (bolus then infusion) were conducted in 40 patients with low-output heart failure (cardiac index
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 1999-06, Vol.83 (12), p.21-25 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 25 |
|---|---|
| container_issue | 12 |
| container_start_page | 21 |
| container_title | The American journal of cardiology |
| container_volume | 83 |
| creator | Folláth, Ferenc Hinkka, Susanna Jäger, Detlef Just, Hanjörg Mitrovic, Veselin Papp, Julius Gy Peuhkurinen, Keijo Sandell, Esa-Pekka Takkunen, Olli Lehtonen, Lasse |
| description | A series of dose-ranging and tolerability studies of intravenous levosimendan (bolus then infusion) were conducted in 40 patients with low-output heart failure (cardiac index |
| doi_str_mv | 10.1016/S0002-9149(99)00314-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_230360437</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914999003148</els_id><sourcerecordid>43291769</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-4159b1d709f152eb8bdfffef19dd4b512c619118bd3c2e86091784cce0f3ea5f3</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EEkPhEZAsVu0i4BsnmZgNQi0_lUbqAlhbjn3dcZWxg3-m7bvxcHhmEAs2rCzb3zlH9x5CXgN7CwyGd98YY20joBPnQlwwxqFrxidkBeNaNCCAPyWrv8hz8iKlu3oF6IcV-XUVEjZR-Vvnb6nyhiZlMT_Se5e31Pkc1R59KInOuA_J7dAb5esHncN9E0peSqZbVDFTq9xcIr6n-LBgdOg1Hri8jYh0cXPINOViHKZjTtXOziMNtiL4r70tyQVP9xhTzTZhKlntDvj55vrq5oLm6NT8kjyzak746s95Rn58_vT98muzuflyfflx02jOu9x00IsJzJoJC32L0zgZay1aEMZ0Uw-tHuqWoD5z3eI4MAHrsdMameWoesvPyJuT7xLDz4Ipy7tQoq-RsuWMD6zj6wr1J0jHkFJEK5fodio-SmDy0JM89iQPJUgh5LEnOVbdh5MO6wR7h1EmfVyecRF1lia4_zj8Bs2Un3U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230360437</pqid></control><display><type>article</type><title>Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial</title><source>Elsevier ScienceDirect Journals</source><creator>Folláth, Ferenc ; Hinkka, Susanna ; Jäger, Detlef ; Just, Hanjörg ; Mitrovic, Veselin ; Papp, Julius Gy ; Peuhkurinen, Keijo ; Sandell, Esa-Pekka ; Takkunen, Olli ; Lehtonen, Lasse</creator><creatorcontrib>Folláth, Ferenc ; Hinkka, Susanna ; Jäger, Detlef ; Just, Hanjörg ; Mitrovic, Veselin ; Papp, Julius Gy ; Peuhkurinen, Keijo ; Sandell, Esa-Pekka ; Takkunen, Olli ; Lehtonen, Lasse</creatorcontrib><description>A series of dose-ranging and tolerability studies of intravenous levosimendan (bolus then infusion) were conducted in 40 patients with low-output heart failure (cardiac index <2.5 L/m
2 per minute). These trials were conducted as preparation for the Levosimendan Infusion versus Dobutamine (LIDO) study, an international, randomized, comparative phase III trial of intravenous levosimendan versus dobutamine in heart failure. Response rates to levosimendan therapy (defined as ≥30% increase in cardiac index during levosimendan administration) were 73–100% (compared with 60% with dobutamine 8–16 μg/kg per minute). Dose dependence was apparent in several hemodynamic responses to levosimendan. From experience in these studies it was concluded that the preferred bolus dose for initiating levosimendan therapy was 12–24 μg/kg, followed by infusion at rates up to 0.4 μg/kg per minute. It was also concluded that, in the dose range identified, levosimendan offered a valid alternative to dobutamine in heart failure patients who require intravenous inotropic support.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/S0002-9149(99)00314-8</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Cardiology ; Clinical trials ; Drug therapy ; Heart failure</subject><ispartof>The American journal of cardiology, 1999-06, Vol.83 (12), p.21-25</ispartof><rights>1999 Excerpta Medica Inc.</rights><rights>Copyright Elsevier Sequoia S.A. Jun 24, 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-4159b1d709f152eb8bdfffef19dd4b512c619118bd3c2e86091784cce0f3ea5f3</citedby><cites>FETCH-LOGICAL-c334t-4159b1d709f152eb8bdfffef19dd4b512c619118bd3c2e86091784cce0f3ea5f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9149(99)00314-8$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids></links><search><creatorcontrib>Folláth, Ferenc</creatorcontrib><creatorcontrib>Hinkka, Susanna</creatorcontrib><creatorcontrib>Jäger, Detlef</creatorcontrib><creatorcontrib>Just, Hanjörg</creatorcontrib><creatorcontrib>Mitrovic, Veselin</creatorcontrib><creatorcontrib>Papp, Julius Gy</creatorcontrib><creatorcontrib>Peuhkurinen, Keijo</creatorcontrib><creatorcontrib>Sandell, Esa-Pekka</creatorcontrib><creatorcontrib>Takkunen, Olli</creatorcontrib><creatorcontrib>Lehtonen, Lasse</creatorcontrib><title>Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial</title><title>The American journal of cardiology</title><description>A series of dose-ranging and tolerability studies of intravenous levosimendan (bolus then infusion) were conducted in 40 patients with low-output heart failure (cardiac index <2.5 L/m
2 per minute). These trials were conducted as preparation for the Levosimendan Infusion versus Dobutamine (LIDO) study, an international, randomized, comparative phase III trial of intravenous levosimendan versus dobutamine in heart failure. Response rates to levosimendan therapy (defined as ≥30% increase in cardiac index during levosimendan administration) were 73–100% (compared with 60% with dobutamine 8–16 μg/kg per minute). Dose dependence was apparent in several hemodynamic responses to levosimendan. From experience in these studies it was concluded that the preferred bolus dose for initiating levosimendan therapy was 12–24 μg/kg, followed by infusion at rates up to 0.4 μg/kg per minute. It was also concluded that, in the dose range identified, levosimendan offered a valid alternative to dobutamine in heart failure patients who require intravenous inotropic support.</description><subject>Cardiology</subject><subject>Clinical trials</subject><subject>Drug therapy</subject><subject>Heart failure</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqFkc1u1DAUhS0EEkPhEZAsVu0i4BsnmZgNQi0_lUbqAlhbjn3dcZWxg3-m7bvxcHhmEAs2rCzb3zlH9x5CXgN7CwyGd98YY20joBPnQlwwxqFrxidkBeNaNCCAPyWrv8hz8iKlu3oF6IcV-XUVEjZR-Vvnb6nyhiZlMT_Se5e31Pkc1R59KInOuA_J7dAb5esHncN9E0peSqZbVDFTq9xcIr6n-LBgdOg1Hri8jYh0cXPINOViHKZjTtXOziMNtiL4r70tyQVP9xhTzTZhKlntDvj55vrq5oLm6NT8kjyzak746s95Rn58_vT98muzuflyfflx02jOu9x00IsJzJoJC32L0zgZay1aEMZ0Uw-tHuqWoD5z3eI4MAHrsdMameWoesvPyJuT7xLDz4Ipy7tQoq-RsuWMD6zj6wr1J0jHkFJEK5fodio-SmDy0JM89iQPJUgh5LEnOVbdh5MO6wR7h1EmfVyecRF1lia4_zj8Bs2Un3U</recordid><startdate>19990624</startdate><enddate>19990624</enddate><creator>Folláth, Ferenc</creator><creator>Hinkka, Susanna</creator><creator>Jäger, Detlef</creator><creator>Just, Hanjörg</creator><creator>Mitrovic, Veselin</creator><creator>Papp, Julius Gy</creator><creator>Peuhkurinen, Keijo</creator><creator>Sandell, Esa-Pekka</creator><creator>Takkunen, Olli</creator><creator>Lehtonen, Lasse</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>19990624</creationdate><title>Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial</title><author>Folláth, Ferenc ; Hinkka, Susanna ; Jäger, Detlef ; Just, Hanjörg ; Mitrovic, Veselin ; Papp, Julius Gy ; Peuhkurinen, Keijo ; Sandell, Esa-Pekka ; Takkunen, Olli ; Lehtonen, Lasse</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-4159b1d709f152eb8bdfffef19dd4b512c619118bd3c2e86091784cce0f3ea5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Cardiology</topic><topic>Clinical trials</topic><topic>Drug therapy</topic><topic>Heart failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Folláth, Ferenc</creatorcontrib><creatorcontrib>Hinkka, Susanna</creatorcontrib><creatorcontrib>Jäger, Detlef</creatorcontrib><creatorcontrib>Just, Hanjörg</creatorcontrib><creatorcontrib>Mitrovic, Veselin</creatorcontrib><creatorcontrib>Papp, Julius Gy</creatorcontrib><creatorcontrib>Peuhkurinen, Keijo</creatorcontrib><creatorcontrib>Sandell, Esa-Pekka</creatorcontrib><creatorcontrib>Takkunen, Olli</creatorcontrib><creatorcontrib>Lehtonen, Lasse</creatorcontrib><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Folláth, Ferenc</au><au>Hinkka, Susanna</au><au>Jäger, Detlef</au><au>Just, Hanjörg</au><au>Mitrovic, Veselin</au><au>Papp, Julius Gy</au><au>Peuhkurinen, Keijo</au><au>Sandell, Esa-Pekka</au><au>Takkunen, Olli</au><au>Lehtonen, Lasse</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial</atitle><jtitle>The American journal of cardiology</jtitle><date>1999-06-24</date><risdate>1999</risdate><volume>83</volume><issue>12</issue><spage>21</spage><epage>25</epage><pages>21-25</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>A series of dose-ranging and tolerability studies of intravenous levosimendan (bolus then infusion) were conducted in 40 patients with low-output heart failure (cardiac index <2.5 L/m
2 per minute). These trials were conducted as preparation for the Levosimendan Infusion versus Dobutamine (LIDO) study, an international, randomized, comparative phase III trial of intravenous levosimendan versus dobutamine in heart failure. Response rates to levosimendan therapy (defined as ≥30% increase in cardiac index during levosimendan administration) were 73–100% (compared with 60% with dobutamine 8–16 μg/kg per minute). Dose dependence was apparent in several hemodynamic responses to levosimendan. From experience in these studies it was concluded that the preferred bolus dose for initiating levosimendan therapy was 12–24 μg/kg, followed by infusion at rates up to 0.4 μg/kg per minute. It was also concluded that, in the dose range identified, levosimendan offered a valid alternative to dobutamine in heart failure patients who require intravenous inotropic support.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/S0002-9149(99)00314-8</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 1999-06, Vol.83 (12), p.21-25 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_journals_230360437 |
| source | Elsevier ScienceDirect Journals |
| subjects | Cardiology Clinical trials Drug therapy Heart failure |
| title | Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T22%3A53%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dose-ranging%20and%20safety%20with%20intravenous%20levosimendan%20in%20low-output%20heart%20failure:%20experience%20in%20three%20pilot%20studies%20and%20outline%20of%20the%20levosimendan%20infusion%20versus%20dobutamine%20(LIDO)%20trial&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Foll%C3%A1th,%20Ferenc&rft.date=1999-06-24&rft.volume=83&rft.issue=12&rft.spage=21&rft.epage=25&rft.pages=21-25&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/S0002-9149(99)00314-8&rft_dat=%3Cproquest_cross%3E43291769%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230360437&rft_id=info:pmid/&rft_els_id=S0002914999003148&rfr_iscdi=true |